A French national breast and thyroid cancer screening programme for survivors of childhood, adolescent and young adult (CAYA) cancers - DeNaCaPST programme

BMC Cancer

Charlotte Demoor-Goldschmidt¹  Angela Jackson¹  Agnès Dumas¹  Florent de Vathaire¹  Brice Fresneau¹  Claire Berger²  Martin Schlumberger³  Bruno Filhon⁴  Dinu Stefan⁵  Céline Vigneron⁶  Marc-André Mahé⁷  Anne Laprie⁸  Valérie Bernier⁹  Julie Leseur^1,10  Sylvie Helfre^1,11  Christine Kerr^1,12  Pierre-Yves Bondiau^1,13  Delphine Drui^1,14  Isabelle Doutriaux^1,15  Nathalie Lassau^1,16  Sandrine Bohrer^1,17  Cécile Faure Conter^1,18  Caroline Oudot^1,19  Stéphanie Proust^2,20  Claire Pluchard^2,21  Hélène Sudour-Bonnange^2,22  Claire Freycon^2,23  Gérard Michel^2,24  Pascal Auquier^2,25 

[1] Centre for Research in Epidemiology and Population Health (CESP), Cancer and Radiation team, INSERM U1018, Université Paris-Sud, UVSQ, Université Paris-Saclay;Claire Berger, hemato-oncology pediatric department, chu nord st Etienne;Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and Université Paris Saclay;Department of Pediatric Hematology and Oncology, Rouen University Hospital;Department of Radiation Oncology, Centre François Baclesse;Department of Radiation Oncology, Centre de lutte contre le Cancer Paul Strauss;Department of Radiation Oncology, ICO;Department of Radiation Oncology, IUCT Oncopole;Department of Radiation Oncology, Institut de Cancérologie de Lorraine;Department of Radiation Oncology, centre Eugène-Marquis;Department of Radiation Oncology, institut Curie;Department of Radiation Oncology, institut du cancer de Montpellier;Department of Radiotherapy, Centre Antoine Lacassagne;Department of endocrinology, CHU de Nantes;Department of radiology, Institut de Cancérologie de l’Ouest – René Gauducheau;Imaging Department, Gustave Roussy Cancer Campus Grand Paris, IR4M UMR8081, Université Paris Sud;Oncology and Hematology Unit, CHU de Saint Denis de La Réunion;Pediatric Oncology Department, Centre Léon-Bérard;Pediatric Oncology Department, Hôpital de la Mère et de l’Enfant;Pediatric Oncology Department, chu Angers;Pediatric Oncology Department, chu Reims, hôpital américain;Pediatric Oncology Unit, Anti Cancer Center Oscar Lambret;Service d’hématologie et d’oncologie pédiatrique du CHU de Grenoble;Service d’hématologie et oncologie pédiatrique, Hôpital d’enfants La Timone;Unité de recherche EA 3279, Université Aix-Marseille;

关键词: Childhood cancer;    Survivor;    Childhood cancer survivor;    Breast cancer screening;    Thyroid cancer screening;    Breast;   

DOI  :  10.1186/s12885-017-3318-1

来源: DOAJ

【 摘 要 】

Abstract Background Survival of childhood, adolescent and young adult (CAYA) cancers has increased with progress in the management of the treatments and has reached more than 80% at 5 years. Nevertheless, these survivors are at great risk of second cancers and non-malignant co-morbidities in later life. DeNaCaPST is a non-interventional study whose aim is to organize a national screening for thyroid cancer and breast cancer in survivors of CAYA cancers. It will study the compliance with international recommendations, with the aim, regarding a breast screening programme, of offering for every woman living in France, at equal risk, an equal screening. Method DeNaCaPST trial is coordinated by the INSERM 1018 unit in cooperation with the LEA (French Childhood Cancer Survivor Study for Leukaemia) study’s coordinators, the long term follow up committee and the paediatric radiation committee of the SFCE (French Society of Childhood Cancers). A total of 35 centres spread across metropolitan France and la Reunion will participate. FCCSS (French Childhood Cancer Survivor Study), LEA and central registry will be interrogated to identify eligible patients. To participate, centers agreed to perform a complete “long-term follow-up consultations” according to good clinical practice and the guidelines of the SFCE (French Society of Children Cancers). Discussion As survival has greatly improved in childhood cancers, detection of therapy-related malignancies has become a priority even if new radiation techniques will lead to better protection for organs at risk. International guidelines have been put in place because of the evidence for increased lifetime risk of breast and thyroid cancer. DeNaCaPST is based on these international recommendations but it is important to recognize that they are based on expert consensus opinion and are supported by neither nonrandomized observational studies nor prospective randomized trials in this specific population. Over-diagnosis is a phenomenon inherent in any screening program and therefore such programs must be evaluated.

【 授权许可】

Unknown